Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.60 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657147 | 0.93 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1MMP13MEN1CRHBP | |
| SCHEMBL658314 | 0.85 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1 | |
| SCHEMBL656842 | 0.82 | HSP90AA1 (0.86) | HSP90AA1HSP90AB1 | |
| SCHEMBL656734 | 0.82 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1MEN1KMT2AFFAR1 | |
| SCHEMBL7890886 | 0.81 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL10147694 | 0.81 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1MEN1KMT2AFFAR1 | |
| SCHEMBL657096 | 0.77 | HSP90AA1 (0.83) | HSP90AA1HSP90AB1 | |
| SCHEMBL657218 | 0.75 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1MEN1KMT2AFFAR1 | |
| SCHEMBL656783 | 0.75 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL7893314 | 0.75 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102438988-B | Resorcinol derivatives as hsp90 inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2015-06-24 | — | — | CN | disclosed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| EP-2421833-B1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-2421833-B1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-01-14 | — | — | EP | disclosed |
| CN-102438988-A | Resorcinol derivatives as hsp90 inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2012-05-02 | — | — | CN | disclosed |
| EP-2421833-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| WO-2010121963-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121963-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885MMP13 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.